- Evaluation of the InCise™ Multileaf
Collimator System Successfully Completed
SUNNYVALE, California,
April 21, 2015 /PRNewswire/ --
Accuray Incorporated (Nasdaq: ARAY) announced today that the
InCise™ Multileaf Collimator (MLC) for the CyberKnife® M6™ System
will now be available outside the United
States in markets where it is approved for sale, in addition
to the U.S. market where the InCise MLC was commercially launched
in February 2015. The launch follows
the successful completion of the evaluation of the InCise MLC by
Erasmus MC Cancer Institute in Rotterdam,
the Netherlands, the European evaluation site working in
collaboration with Accuray. Two sites in the U.S. had previously
completed their successful evaluation of the InCise MLC. The main
benefits of the MLC reported by the sites were the ability to treat
a broader range of tumors than they could with fixed collimators or
the Iris™ Collimator, and to do so with significantly increased
efficiency. The InCise MLC will be featured at the European Society
for Therapeutic Radiology and Oncology (ESTRO) meeting in
Barcelona, Spain, April 24 – 27, 2015.
"We are continuing to advance our successful CyberKnife M6
System platform, through the introduction of the InCise MLC. The
addition of the InCise MLC enhances the M6 system's functionality
by significantly reducing treatment times and expands its
versatility by broadening the range of patients and tumors that can
be treated," said Joshua H. Levine,
president and chief executive officer of Accuray. "We believe the
M6, with the MLC, will enable clinicians to treat tumors they may
have thought to be untreatable with SBRT, efficiently and with
precise dose delivery."
The InCise MLC is the world's first multileaf collimator to be
available on a robotic platform, the CyberKnife M6 System. The
system's robotic design enables physicians to find the best angles
for radiation to enter and exit the body, thus maximizing dose to
the target while minimizing exposure to healthy tissue. The robotic
design also enables the system to adjust and automatically stay on
target in real-time, accounting for patient and tumor motion. The
CyberKnife M6 System can be used to treat tumors anywhere in the
body, including the prostate, lung, brain, spine, liver, pancreas
and kidney, and may offer hope to patients who have inoperable or
surgically complex tumors, or who may prefer a clinically
effective, non-surgical option.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative tumor
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to advantages of new
technology, clinical applications, clinical results, patient
outcomes and Accuray's leadership position in radiation oncology
innovation and technologies. Forward-looking statements are subject
to risks and uncertainties that could cause actual results to
differ materially from expectations, including but not limited to
the market's failure to adopt our new product offerings and the
risks detailed under the heading "Risk Factors" in the company's
report on Form 10-K, filed on August 29,
2014, the company's reports on Form 10-Q, filed on
November 7, 2014 and February 6, 2015, and the company's other filings
with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.